Table 1. Patient characteristics.
| All women | Pre-menopausal | Post-menopausal | |
|---|---|---|---|
| n = 162 | n = 81 | n = 81 | |
| Number (%) | |||
| Age (mean ± SD, years) | 52.6 ± 7.9 | 46.8 ± 5.8 | 58.3 ± 4.9 |
| BMI (mean ± SD, kg/m2) | 27.0 ± 5.6 | 26.3 ± 5.6 | 27.7 ± 5.5 |
| <25 | 67 (41.4) | 39 (48.2) | 28 (34.6) |
| 25-<30 | 59 (36.4) | 29 (35.8) | 30 (37.0) |
| ≥30 | 36 (22.2) | 13 (16.1) | 23 (28.4) |
| Smoking status | |||
| Never | 69 (42.6) | 41 (50.6) | 28 (34.6) |
| Former | 72 (44.4) | 29 (35.8) | 43 (53.1) |
| Current | 21 (13.0) | 11 (13.6) | 10 (12.4) |
| Alcohol consumption (mean ± SD, drink per week) | 4.3 ± 4.6 | 4.5 ± 4.2 | 4.1 ± 5.0 |
| Physical activity (mean ± SD, MET-hours per week) | |||
| Total | 118.6 ± 51.4 | 137.5 ± 47.2 | 99.7 ± 48.6 |
| Occupational | 63.6 ± 45.6 | 79.9 ± 37.6 | 47.4 ± 47.3 |
| Transportation-related | 0.7 ± 2.0 | 0.8 ± 2.3 | 0.7 ± 1.7 |
| Household | 36.0 ± 23.3 | 36.2 ± 24.0 | 35.7 ± 22.6 |
| Recreational | 18.3 ± 17.0 | 20.6 ± 19.1 | 16.0 ± 14.3 |
| Stage | |||
| 0 | 16 (9.9) | 9 (11.1) | 7 (8.6) |
| I | 64 (39.5) | 33 (40.7) | 31 (38.3) |
| II | 66 (40.7) | 35 (43.2) | 31 (38.3) |
| III | 16 (9.9) | 4 (5.0) | 12 (14.8) |
| Histological type | |||
| Ductal, in-situ | 16 (9.9) | 9 (11.1) | 7 (8.6) |
| Ductal, invasive | 121 (74.7) | 66 (81.5) | 55 (67.9) |
| Lobular, invasive | 15 (9.3) | 4 (4.9) | 11 (13.6) |
| Others* | 10 (6.1) | 2 (2.5) | 8 (9.9) |
| Tumor grade | |||
| Non-assessable | 26 (16.0) | 11 (13.6) | 15 (18.5) |
| 1 | 29 (17.9) | 15 (18.5) | 14 (17.3) |
| 2 | 68 (42.0) | 36 (44.4) | 32 (39.5) |
| 3 | 39 (24.1) | 19 (23.5) | 20 (24.7) |
| ER status | |||
| Positive | 145 (89.5) | 74 (91.4) | 71 (87.6) |
| Negative | 17 (10.5) | 7 (8.6) | 10 (12.4) |
| PR status | |||
| Positive | 136 (84.0) | 74 (91.4) | 62 (76.5) |
| Negative | 26 (16.0) | 7 (8.6) | 19 (23.5) |
| HER2 status | |||
| Not evaluated | 28 (17.3) | 11 (13.6) | 17 (21.0) |
| Positive | 18 (11.1) | 8 (9.9) | 10 (12.3) |
| Negative | 116 (71.6) | 62 (76.5) | 54 (66.7) |
SD: Standard deviation; BMI: Body mass index; MET-hours: metabolic equivalent hours of activity; ER: Estrogen receptor; PR: Progesterone receptor; HER2: Human epidermal growth factor receptor 2
*: includes mucinous, tubular, adenoid cystic and metaplastic carcinomas